Creative Medical Technology Holdings, Inc. (CELZ)
NASDAQ: CELZ · Real-Time Price · USD
3.085
+0.165 (5.65%)
Aug 12, 2025, 4:00 PM - Market closed
Nordstrom Revenue
Creative Medical Technology Holdings had revenue of $6.00K in the twelve months ending June 30, 2025, down -64.71% year-over-year. In the year 2024, Creative Medical Technology Holdings had annual revenue of $11.00K with 22.22% growth.
Revenue (ttm)
$6.00K
Revenue Growth
-64.71%
P/S Ratio
1,326.82
Revenue / Employee
$1,500
Employees
4
Market Cap
7.96M
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 11.00K | 2.00K | 22.22% |
| Dec 31, 2023 | 9.00K | -79.60K | -89.84% |
| Dec 31, 2022 | 88.60K | 846.00 | 0.96% |
| Dec 31, 2021 | 87.75K | -76.75K | -46.65% |
| Dec 31, 2020 | 164.50K | -1.00K | -0.60% |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| UnitedHealth Group | 422.82B |
| Johnson & Johnson | 90.63B |
| Merck & Co. | 63.62B |
| AbbVie | 58.33B |
| AstraZeneca | 56.50B |
| Novartis AG | 55.19B |
| Eli Lilly and Company | 53.26B |
| Novo Nordisk | 49.11B |
CELZ News
- 26 days ago - Creative Medical Technology Holdings Receives Notice of Allowance for the Prevention and/or Treatment of Type 1 Diabetes Using Modulated Immune Cells - GlobeNewsWire
- 4 weeks ago - Creative Medical Technology Holdings Receives Notice of Allowance for ImmCelz™ for Treatment of Heart Failure and/or Post Infarct Pathological Remodeling - GlobeNewsWire
- 5 months ago - Creative Medical Technology Holdings Secures FDA Clearance for Expanded Dose Escalation in the Clinical Trial of CELZ-201-DDT for Chronic Lower Back Pain - GlobeNewsWire
- 5 months ago - Creative Medical Technology Holdings Announces Agreements for Exercise of Warrants for $3.7 Million Gross Proceeds - GlobeNewsWire
- 6 months ago - Creative Medical Technology Holdings Announces Mid-Term Follow-up Study Data Reporting Significant Reduction in Opioid Use by Chronic Lower Back Pain Patients Undergoing StemSpine® Procedure using AlloStem™ - GlobeNewsWire
- 6 months ago - Creative Medical Technology Reports Positive One-Year Results for AlloStem™ Type 2 Diabetes Program - GlobeNewsWire
- 6 months ago - Creative Medical Technology Holdings Expands Collaboration with Greenstone Biosciences to Accelerate iPSCelz Pipeline Development - GlobeNewsWire
- 6 months ago - Creative Medical Technology Holdings Announces Positive Initial Safety, Tolerability, and Efficacy Data from First Cohort in Phase 1/2 Trial of CELZ-201-DDT for Chronic Back Pain - GlobeNewsWire